Kura Oncology(KURA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Kura Oncology reported net product revenue of $2.1 million from Komzifti sales in Q4 2025, compared to none in Q4 2024 [16] - Collaboration revenue from the partnership with Kyowa Kirin was $15.2 million, down from $53.9 million in the same period in 2024 [16] - Research and development expenses increased to $64.4 million from $52.3 million in Q4 2024, driven by ziftomenib combination trials [16] - Sales, general, and administrative expenses rose to $39.1 million from $24.1 million in Q4 2024, attributed to the commercial launch of Komzifti [17] - The net loss for Q4 2025 was $81 million, compared to a net loss of $19.2 million in Q4 2024 [17] - Cash equivalents and short-term investments as of December 31, 2025, were $667.2 million, down from $727.4 million at the end of 2024 [17] Business Line Data and Key Metrics Changes - Komzifti generated $2.1 million in net product revenue shortly after its launch, indicating a strong start [3] - The initial U.S. market for NPM1-mutated relapse refractory AML is estimated at approximately $350 million to $400 million annually [10] - Kura anticipates a total U.S. opportunity across relapsed refractory and frontline AML of approximately $7 billion [4] Market Data and Key Metrics Changes - Prescription trends for Komzifti are strong, with positive feedback from physicians and pharmacists regarding its clinical activity and ease of use [7] - Approximately 84% of private payers established coverage for Komzifti within 90 days of approval, surpassing industry benchmarks [9] - Certain blue plans are requiring patients to use Komzifti before allowing coverage for other approved menin inhibitors, indicating a competitive advantage [9] Company Strategy and Development Direction - Kura's strategy focuses on executing commercially, expanding development of ziftomenib across the AML treatment continuum, and advancing a pipeline with meaningful catalysts in 2026 [5] - The company aims to position ziftomenib as a foundational combination partner in AML, including with FLT3 inhibitors and standard backbone regimens [4] - Kura is advancing a focused solid tumor strategy alongside its AML initiatives [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong early launch of Komzifti and its potential to establish leadership in the menin inhibitor class [6] - The company is focused on quarter-over-quarter growth, net revenue, and new patient starts, with plans to provide additional metrics to track progress [10] - Management highlighted the importance of combination therapies in driving better outcomes for patients and gaining market share [42] Other Important Information - Komzifti is now listed in the FDA's Orange Book with patent protection through July 2044, enhancing the long-term value of the franchise [4] - Kura expects to provide guidance for collaboration revenue of $45 million to $55 million in 2026, with anticipated milestones of $180 million under the collaboration agreement with Kyowa Kirin [18] Q&A Session Summary Question: Can you provide more information about the step editing policy from payers? - Management noted that some payers are recommending Komzifti before other menin inhibitors based on its differentiated profile, particularly its cost predictability and safety [25][26] Question: Can you comment on patient demand versus revenue generation? - Management indicated that the launch has been strong, with positive feedback from physicians and expectations for increased patient demand as more data becomes available [33] Question: What do you see as the biggest hurdle for Komzifti to gain market share in 2026? - Management identified the need to get incident patients onto therapy as a key challenge, with no significant payer hurdles reported [40] Question: How do you plan to maximize the FLT3 opportunity? - Management emphasized the importance of combining ziftomenib with FLT3 inhibitors to capture a significant portion of the AML market, as FLT3 mutations represent a large patient population [64] Question: What are the expectations for duration of therapy with Komzifti? - Management stated that while it is early to provide specific data, they expect patients to be treated for up to six months, with ongoing assessments of treatment duration as more data becomes available [87]